Enterotoxigenic Escherichia coli (ETEC) is the leading cause of bacterial diarrhea in young children in developing countries. The safety and immunogenicity of a killed, oral ETEC vaccine consisting of whole cells plus recombinantly produced cholera toxin B subunit (rCTB) was evaluated in Egypt, which is endemic for ETEC diarrhea. Seventy-four healthy Egyptian adults (21 -45 years old) were randomized and received two doses of the ETEC/rCTB vaccine (E003) or placebo 2 weeks apart. The frequency of adverse events after either dose did not differ by treatment group, and no severe adverse events were reported. After vaccination, peripheral blood IgA B cell responses to CTB (100%) and to vaccine colonization factor antigens CFA/I (94%), CS4 (100%), CS2 (81%), and CS1 (69%) were significantly higher than response rates for the placebo group. These favorable results in Egyptian adults indicate that the ETEC/rCTB vaccine is a promising candidate for evaluation in younger age groups in this setting.
Because enterotoxigenic Escherichia coli (ETEC) -associ-E003, were safe and stimulated relevant mucosal immune responses in Swedish and Bangladeshi adult volunteers [6, 7, 7a ] ated diarrhea causes considerable morbidity and mortality in young children residing in developing countries and is a princi-(Qadri F, unpublished data). In preparation for a field trial in Egypt, where ETEC is endemic among young children [8] , we pal cause of traveler's diarrhea, development of a safe, effective ETEC vaccine has been accorded a high priority [1] . An oral, initiated a sequential series of studies to establish the safety and immunogenicity of the ETEC/rCTB vaccine in descending formalin-killed whole cell ETEC plus recombinant cholera toxin B subunit (ETEC/rCTB) vaccine was developed on the age groups. Here we present the results of the first of these studies, a randomized, double-blinded, placebo-controlled trial premises that oral vaccination is the most efficient way of eliciting mucosal immune responses and that antibacterial and in Egyptian adults. antitoxic immunity act synergistically to protect against ETEC diarrhea [2, 3] . In addition, oral immunization with CTB has Materials and Methods been shown to protect against ETEC producing the antigeniPopulation and eligibility. Healthy men and women cally similar heat-labile enterotoxin (LT) [4, 5] . In previous years old) were recruited from the staff of two health service trials, two formulations of the ETEC/rCTB vaccine, E001 and facilities in Benha, Egypt. Excluded from participation were subjects with a history of chronic gastrointestinal illness, diarrhea, antidiarrheal drug usage, febrile illness in the week before dosing, or pregnancy. Received 7 February 1997; revised 22 September 1997. Vaccine and placebo composition. The ETEC/rCTB vaccine Presented in part: 96th general meeting of the American Society of Microbi-(E003) was produced by SBL Vaccin (Stockholm). One 4-mL ology, New Orleans, 19 -23 May 1996 (abstract E-32) .
Informed consent was obtained from all subjects, and the human use guidevaccine dose contained 1.0 mg of rCTB plus Ç2 1 10 10 formalinlines of the US Department of Defense were followed in the conduct of this inactivated bacteria of each of the following ETEC isolates: Surveillance for side effects. Subjects had oral temperatures
taken and underwent a standardized, structured interview on 3 consecutive days after each dose. This interval was selected since
No symptoms 30 (79) 22 (58) 27 (75) 24 (63) most temporally associated symptoms were observed during this Diarrhea 1 (3) 0 2 (6) 1 (3) Nausea 2 (5) 5 (13) 1 (3) 4 (11) time period in preceding clinical studies with this vaccine [6, 7, Vomiting 0 1 (3) 2 (6) 2 (5) 7a] (Qadri F, unpublished data). The occurrence of specific gastroAbdominal pain 3 (8) 7 (18) 3 (8) 9 (24) intestinal symptoms and other unanticipated complaints was ascerAppetite loss 2 (5) 4 (11) 1 (3) 2 (5) tained, and reported symptoms were graded as mild (noticeable), Other* 7 (18) 9 (24) 7 (20) 10 (26) moderate (affecting normal daily activities), or severe (suspending normal daily activities). Before the study was begun, diarrhea was Microbiologic studies. Stool samples were collected from sub-1 each 7 days after the first and second doses. Blood was collected jects before the initial dosing and from subjects reporting diarrhea in heparinized tubes and held at 15-25ЊC. Assessment of antibody during surveillance after dosing. Samples were processed and evalsecretion using peripheral blood mononuclear cells (PBMC) was uated, using standard methods, for the presence of bacterial and initiated within 5 h of collection. IgA antibody-secreting cell parasitic enteropathogens. As part of the diagnostic evaluation, 5 (ASC) responses were chosen as the primary end points for immulactose-fermenting colonies were tested for LT and STa enteronologic evaluation, since previous studies have suggested them to toxin production by GM1 ELISA as previously described [10, 11] . be indicators of local intestinal immune responses [6, 7] . Because
Enterotoxin-positive isolates were tested for expression of CFA/I, this assay requires considerable time and fresh PBMC, a limited CS1, CS2, CS3, CS4, CS5, CS6, CFA/III, CS7, CS17, PCFO159, number of samples could be processed daily. Hence, ASC analysis and PCFO166 by monoclonal antibody dot blot assay [12] . was confined to the first 32 subjects enrolled before the first dose.
Statistical analyses. All subjects receiving a dose of study PBMC were isolated from the blood cellular fraction by ficollagent were included in the post-dosing safety analysis. For each hypaque gradient centrifugation. The total number of IgA ASCs symptom, proportions were compared using Fisher's exact test and antigen-specific IgA ASCs was measured in fresh PBMC by [13] . This test was also used to assess differences in ASC response use of the ELISPOT assay [7, 9] . Individual wells of nitrocellulosebetween the 2 treatment groups after each dose. P values were bottomed plates were coated with 0.1 mL of purified CFA/I, CS1, adjusted for confounding values in stratified analyses using the CS2, CS4, or GM1 ganglioside overnight at 4ЊC. The choice of Mantel-Haenszel test. The median number of ASCs was compared CFA/II and CFA/IV subcomponents used in immunologic studies between treatment groups after each dose by the median test. All was dictated by availability of sufficiently pure lots of antigen. statistical tests were interpreted in a two-tailed fashion. After a PBS wash, the GM1-coated wells were exposed to CTB for 2 h at 37ЊC. After being washed with PBS, the plates were blocked with Iscove's complete medium supplemented with 5% Results fetal calf serum and 50 mg/mL gentamicin. A 0.1-mL suspension Of 83 persons who were screened for eligibility, 82 met of PBMC was added to each well, and plates were incubated for inclusion criteria and 6 refused participation. Overall, 74 sub-3 h at 37ЊC in 7.5% CO 2 . The total number of added PBMC per jects received both doses of vaccine or placebo, and 2 received well was 5 1 10 5 for CTB and 1 1 10 6 for colonization factor the first dose only. The 2 subjects were excluded from the antigens (CFA). Plates were then washed, incubated overnight at 4ЊC with goat anti-human IgA horseradish peroxidase, and exposed second dose because of absenteeism or intercurrent diarrhea. reporting specific complaints, there were no significant differdone in adult Swedish subjects who lacked preexisting immunity to ETEC [6, 7, 7a] . In those studies, satisfactory vaccine ences in risks by treatment group, though there was a trend toward a higher risk of nausea and abdominal cramps in vaccinsafety and immunogenicity were demonstrated. Whether or not those encouraging results apply to populations in which ETEC ees after each dose. All reported complaints were graded as mild, with the exception of those for 2 vaccinees and 1 placebo is endemic is now beginning to be addressed (Qadri F, unpublished data) . The present report shows that the ETEC/rCTB recipient who reported symptoms of moderate grade.
Diarrhea and vomiting were infrequently reported after either vaccine can be safely administered to Egyptian adults with induction of mucosal immune responses to both toxoid and dose. Of the four episodes of diarrhea, three lasted 1 day and one lasted 2 days. The total number of soft or liquid stools cellular vaccine components. passed ranged from 3 to 8. Of the 5 subjects with vomiting, 4
The ETEC/rCTB vaccine was well tolerated by subjects in experienced a single bout of emesis, while 1 subject vomited this trial: No severe reactions were observed. There was no three times. All episodes of vomiting or diarrhea were mild, significantly increased risk of diarrhea, vomiting, or other gasand no volunteer required medical attention for these problems.
trointestinal symptoms attributable to vaccination. These findWomen were more likely than men to report symptoms after ings indicate an acceptable safety profile of this vaccine in either dose; however, this was statistically significant only after Egyptian adults. the first dose (odds ratio Å 2.89; 95% confidence intervals Å Following ETEC/rCTB oral immunization, Egyptian adults 1.06, 7.87). However, sex-adjusted analyses for risk of sympexhibited prompt ASC responses to CTB, CFA/I, and subcomtoms in the vaccine versus placebo group by the Mantel-Haensponent antigens of CFA/II and CFA/IV. Responses to most zel method yielded nonsignificant odds ratios.
antigens were maximal after the first vaccine dose, although ASC responses. A complete series of 3 separate blood samsome recruitment of response to CTB, CS1 and CS2 was seen ples was available for measurement of circulating IgA ASCs for after the second dose. For some antigens, a notable proportion 27 subjects, while 5 subjects had only the 2 post-dosing speciof placebo recipients exhibited an ASC response. It is unlikely mens tested. The cumulative proportion responding to either a that this was due to intercurrent asymptomatic ETEC infection first or a second dose of vaccine was ú80% for all antigens since no subject in the ASC subsample had a documented LT / except CS1 (69%) and was significantly higher in vaccinees than or vaccine-related CFA / ETEC infection. Alternatively, the in placebo recipients for all antigens (table 2). One subject in cutoff value for a positive response may not have been suffithe subsample undergoing ASC measurements was found to be ciently stringent to discriminate clearly positive responses in infected with an ETEC isolate (ST / , CFA 0 ) at baseline.
an ETEC endemic population. After the first dose, the median number of ASCs to all tested Reviewing accumulated ELISPOT data from Swedish volunantigens was significantly higher in the vaccine group than in teers receiving the ETEC/rCTB vaccine, a slightly more strinthe placebo group (table 2). The same was true after the second gent criterion for positive response has been advocated, requirdose for CTB and CFA/I only. Among vaccinees, the median ing a minimum of ú10 per 10 7 PBMC post-immunization number of ASCs was greater after the first dose than after (Svennerholm AM, personal communication) . Applying this the second dose for all antigens, and these differences were modified criteria to the present trial, slightly lower cumulative statistically significant (P õ .05) for CS1, CS2, and CS4.
response rates were noted for all CFA antigens in both the vaccine and placebo groups, but the newer criterion provided Discussion no greater discrimination between groups (data not shown). Based on our findings, it could be argued that a single dose Most previously reported human trials with the present killed oral ETEC/rCTB vaccine and its earlier versions have been of ETEC/rCTB vaccine is adequate for stimulation of suitable
